Alnylam Pharmaceuticals Canada ULC

Silver Sponsor

Focus: Neurology – Hereditary Transthyretin Amyloidosis (hATTR) and Acute Hepatic Porphyrias (AHP)

Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a deep pipeline of investigational medicines including Alnylam’s first RNAi therapeutic for hereditary ATTR (hATTR) amyloidosis currently under Priority Review by Health Canada.  Alnylam employs over 1000 people worldwide with Canadian headquarters in Mississauga, Ontario.